Growth Metrics

Travere Therapeutics (TVTX) Change in Acquisitions & Divestments (2016 - 2025)

Travere Therapeutics' Change in Acquisitions & Divestments history spans 13 years, with the latest figure at $82.4 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments rose 49.72% year-over-year to $82.4 million; the TTM value through Dec 2025 reached $323.6 million, down 0.84%, while the annual FY2025 figure was $323.6 million, 0.84% down from the prior year.
  • Change in Acquisitions & Divestments reached $82.4 million in Q4 2025 per TVTX's latest filing, down from $106.6 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $152.6 million in Q2 2022 to a low of $50.0 million in Q4 2023.
  • Average Change in Acquisitions & Divestments over 5 years is $90.0 million, with a median of $88.7 million recorded in 2021.
  • Peak YoY movement for Change in Acquisitions & Divestments: soared 210.05% in 2021, then tumbled 57.54% in 2022.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $57.5 million in 2021, then fell by 8.91% to $52.4 million in 2022, then fell by 4.55% to $50.0 million in 2023, then grew by 10.1% to $55.0 million in 2024, then skyrocketed by 49.72% to $82.4 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Change in Acquisitions & Divestments are $82.4 million (Q4 2025), $106.6 million (Q3 2025), and $81.4 million (Q2 2025).